First Header Logo Second Header Logo

Connection

Karl-Erik Andersson to Cancer Vaccines

This is a "connection" page, showing publications Karl-Erik Andersson has written about Cancer Vaccines.
Connection Strength

0.210
  1. Hillerdal V, Boura VF, Björkelund H, Andersson K, Essand M. Avidity characterization of genetically engineered T-cells with novel and established approaches. BMC Immunol. 2016 07 13; 17(1):23.
    View in: PubMed
    Score: 0.122
  2. Huijbers EJ, Femel J, Andersson K, Björkelund H, Hellman L, Olsson AK. The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-B--a prerequisite for clinical development. Vaccine. 2012 Jan 05; 30(2):225-30.
    View in: PubMed
    Score: 0.088
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.